Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in G20 countries has seen significant growth in recent years due to the increasing prevalence of cancer and the rising demand for effective treatments.
Customer preferences: Customers in the Oncology Drugs market are primarily looking for drugs that are highly effective in treating cancer while also minimizing side effects. They are also increasingly interested in personalized medicine, which involves tailoring treatments to individual patients based on their genetic makeup.
Trends in the market: In the United States, the largest market for Oncology Drugs, the trend towards personalized medicine has led to the development of targeted therapies that are designed to specifically treat certain types of cancer. In Europe, the focus has been on developing biosimilars, which are less expensive versions of existing biologic drugs. In Japan, the market for Oncology Drugs has been driven by the government's efforts to increase access to cancer treatments.
Local special circumstances: In China, the Oncology Drugs market has seen rapid growth due to the country's aging population and the increasing prevalence of cancer. The Chinese government has also been investing heavily in the development of new cancer treatments, which has helped to spur growth in the market. In India, the market for Oncology Drugs has been driven by the increasing prevalence of cancer and the country's growing middle class, which has led to greater demand for high-quality medical treatments.
Underlying macroeconomic factors: The Oncology Drugs market in G20 countries is also influenced by a number of macroeconomic factors, including government regulations, healthcare policies, and economic growth. In countries with strong healthcare systems and robust economies, such as the United States, Japan, and Germany, the market for Oncology Drugs is well-established and continues to grow. In emerging markets, such as China and India, the market for Oncology Drugs is still developing and is expected to see significant growth in the coming years. Overall, the Oncology Drugs market in G20 countries is expected to continue to grow as the prevalence of cancer increases and new treatments are developed to meet the needs of patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
